News
David Heal contributes to new article 'Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling'
Read More
We are pleased to announce that 'Preclinical evaluation of the abuse potential of purified botanical cannabidiol' was the JPET Editor's Choice in July 2022.
Read More
Congratulations to Eloise Kuijer, our PhD student with the University of Bath, for presentation of a poster at INRC 2022
Read More
DevelRx announces publication of book chapter 'New Drugs to treat ADHD: Opportunities and Challenges in Research and Development'
Read More
David Heal becomes Scientific Advisor for company developing novel psychedelics
Read More
DevelRx to participate in Workshop 'Key considerations in planning, interpreting and reporting animal model studies relevant to psychiatric illness' Join us at the BAP Summer Meeting, London, UK, 24th July 2022
Read More
Improving the validity and translation of preclinical research
Read More
DevelRx contribute to new publication showing that ulotaront, a novel TAAR1 agonist with 5-HT1A agonist activity, lacks abuse liability and may have potential for the treatment of substance use disorders
Read More
Read our comprehensive review about the development of drugs to treat binge-eating disorder
Read More
DevelRx and The Canna Consultants raise concerns about the scientifically unjustified, and ethically unacceptable, replicate toxicity testing of cannabidiol demanded by the Food Standards Agency
Read More
Sharon Smith joins Editorial Board of Neuropharmacology
Read More
We invite you to attend our presentation ‘Psychedelics and CNS Drugs with Novel Mechanisms. Non-clinical Abuse Evaluations to Meet the Challenge’ Continuing Education Course, Virtual SPS Meeting, October 2021
Read More
The Next Trip - Developing the Second Generation of Psychedelics and their Analogs for Targeted Medical Use. Watch our podcast on 21st September 2021
Read More
Congratulations to Cara Therapeutics and Vifor Pharma on the FDA approval of Korsuva
Read More
What are the prospects for new drugs for binge-eating disorder?
Read More
DevelRx announces collaboration with Scitegrity
Read More
Does every CNS drug-candidate require a program of GLP non-clinical abuse potential testing?
Read More
Join us at the 83rd Annual Scientific Virtual Meeting of the CPDD, 21st- 24th June, 2021
Read More
How can non-clinical research inform the clinical development and prescribing of psychedelic drugs?
Read More
Congratulations to our colleague, Dr Jo Palandri, on her recent publication in the Journal of Psychopharmacology!
Read More
How do we Adapt to Continue Making Accurate, Experimental-Based Predictions of Drug Abuse Risks? DevelRx takes great pleasure to announce that we will be co-hosting a workshop at the 83rd Annual Scientific Virtual Meeting of the College on Problems of Drug Dependence (CPDD) conference, June 19th - 23rd 2021:
Read More
DevelRx was very pleased to assist Always Pure Organics with the preparation of their three dossiers that were submitted to the FSA last month for Cannabidiol (CBD)-based Novel Foods; one for their Swiss Isolate, one for their Colombian Isolate and one for their Colombian Distillate.
Read More
BPS, LASA & Psychiatry Consortium joint workshop: Exploring the Status of Preclinical Models of Psychiatric Disorders - Their Validity and Scope for Successful Translation - 25th February 2021
Read More
DevelRx continues its medical education support for psychiatrists and other healthcare providers treating attention deficit hyperactivity disorder.
Read More
Professor David Heal will be co-presenting two posters at the American College of Neuropsychopharmacology (ACNP) 59th Annual Meeting - Virtual Conference to be held from 6th to 9th December, 2020.
Read More
David Heal will give a presentation at the American College of Toxicology Virtual Meeting (November 12th to 19th 2020) as part of the Continuing Education Course—CE07 entitled “Understanding the Assessment of Abuse Potential: Industry and Regulatory Perspective”
Read More
Professor David Heal, Dr Sharon Smith and Dr Reem Elbekai will be co-presenting two posters on Centanafadine at the American College of Toxicology (ACT) Virtual Meeting (November 12th to 19th 2020).
Read More
DevelRx is delighted to announce that the University of Bath and DevelRx have agreed to co-sponsor a PhD project entitled “Mu and kappa opioid receptors in addictive behaviour”.
Read More
Biocity,
Pennyfoot Street,
Nottingham,
Nottinghamshire,
NG1 1GF